Skip to content
Tesamorelin.app

Bibliography

Tesamorelin publications

The 20 peer-reviewed publications this site cites, newest first, each with a one-line description of what it measured. The 11 registered trials behind them are in the trial explorer.

By Tesamorelin.app editorial teamSources reviewed How we source

  1. 2026Pilot RCT

    10-week pilot (n = 22). Measured cognition and brain connectivity.

    Stewart CE, et al. The effect of growth hormone-releasing hormone on cognition and brain connectivity in adults with cognition ranging from normal to mild cognitive impairment. eNeurologicalSci. 2026;44:100616. PubMed · PMID 42382101 · doi:10.1016/j.ensci.2026.100616 · accessed 2026-11-11

  2. 2026Meta-analysis

    Systematic review of four RCTs in HIV-associated lipodystrophy.

    Ditta AM, et al. Efficacy and safety of tesamorelin in people living with HIV with lipodystrophy: a systematic review and meta-analysis. J Int Assoc Provid AIDS Care. 2026;25. PubMed · PMID 42538058 · doi:10.1177/23259582261475549 · accessed 2026-11-11

  3. 2026Meta-analysis

    Meta-analysis of five placebo-controlled RCTs in HIV-associated lipodystrophy.

    Badran AS, et al. Body composition, hepatic fat, metabolic, and safety outcomes of tesamorelin, a GHRH analogue, in HIV-associated lipodystrophy: a meta-analysis of randomized controlled trials. Obes Res Clin Pract. 2026;20:2-12. PubMed · PMID 41545261 · doi:10.1016/j.orcp.2026.01.002 · accessed 2026-11-11

  4. 2025Randomized, no placebo

    Neurocognitive measures in HIV with abdominal obesity. No significant between-group difference.

    Ellis RJ, et al. Effects of tesamorelin on neurocognitive impairment in persons with HIV and abdominal obesity. J Infect Dis. 2025;231:1230-1238. PubMed · PMID 39813152 · doi:10.1093/infdis/jiaf012 · accessed 2026-11-11

  5. 2024Post hoc subgroup

    Participants on integrase inhibitors in the liver-fat trial.

    Russo SC, et al. Efficacy and safety of tesamorelin in people with HIV on integrase inhibitors. AIDS. 2024;38:1758-1764. PubMed · PMID 38905488 · doi:10.1097/QAD.0000000000003965 · accessed 2026-11-11

  6. 2019RCT

    12-month two-centre trial. Measured hepatic fat fraction in HIV with liver fat of 5% or more.

    Stanley TL, et al. Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial. Lancet HIV. 2019;6:e821-e830. PubMed · PMID 31611038 · doi:10.1016/S2352-3018(19)30338-8 · accessed 2026-11-11

  7. 2017RCT

    12-week safety and glucose study in adults with type 2 diabetes.

    Clemmons DR, et al. Safety and metabolic effects of tesamorelin, a growth hormone-releasing factor analogue, in patients with type 2 diabetes: a randomized, placebo-controlled trial. PLoS One. 2017;12:e0179538. PubMed · PMID 28617838 · doi:10.1371/journal.pone.0179538 · accessed 2026-11-11

  8. 2014RCT

    6-month single-centre trial. Measured visceral fat and liver fat in HIV with abdominal fat accumulation.

    Stanley TL, et al. Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial. JAMA. 2014;312:380-9. PubMed · PMID 25038357 · doi:10.1001/jama.2014.8334 · accessed 2026-11-11

  9. 2014Phase 2 RCT

    Ipamorelin in postoperative ileus. Comparison reference.

    Beck DE, et al. Prospective, randomized, controlled, proof-of-concept study of the ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients. Int J Colorectal Dis. 2014;29:1527-34. PubMed · PMID 25331030 · doi:10.1007/s00384-014-2030-8 · accessed 2026-11-11

  10. 2013RCT substudy

    Brain neurotransmitter measures by MR spectroscopy in the same older-adult cohort.

    Friedman SD, et al. Growth hormone-releasing hormone effects on brain γ-aminobutyric acid levels in mild cognitive impairment and healthy aging. JAMA Neurol. 2013;70:883-90. PubMed · PMID 23689947 · doi:10.1001/jamaneurol.2013.1425 · accessed 2026-11-11

  11. 2012Post hoc analysis

    Compared metabolic measures between VAT responders and non-responders in the phase 3 trials.

    Stanley TL, et al. Reduction in visceral adiposity is associated with an improved metabolic profile in HIV-infected patients receiving tesamorelin. Clin Infect Dis. 2012;54:1642-51. PubMed · PMID 22495074 · doi:10.1093/cid/cis251 · accessed 2026-11-11

  12. 2012RCT

    12-month trial in abdominal obesity without HIV. Measured VAT, carotid IMT, lipids and IGF-1.

    Makimura H, et al. Metabolic effects of a growth hormone-releasing factor in obese subjects with reduced growth hormone secretion: a randomized controlled trial. J Clin Endocrinol Metab. 2012;97:4769-79. PubMed · PMID 23015655 · doi:10.1210/jc.2012-2794 · accessed 2026-11-11

  13. 2012RCT

    20-week trial of cognitive measures in healthy older adults and adults with mild cognitive impairment.

    Baker LD, et al. Effects of growth hormone-releasing hormone on cognitive function in adults with mild cognitive impairment and healthy older adults: results of a controlled trial. Arch Neurol. 2012;69:1420-9. PubMed · PMID 22869065 · doi:10.1001/archneurol.2012.1970 · accessed 2026-11-11

  14. 2011Physiology

    Uncontrolled 2-week study in 13 healthy men. Measured GH pulsatility and insulin sensitivity.

    Stanley TL, et al. Effects of a growth hormone-releasing hormone analog on endogenous GH pulsatility and insulin sensitivity in healthy men. J Clin Endocrinol Metab. 2011;96:150-8. PubMed · PMID 20943777 · doi:10.1210/jc.2010-1587 · accessed 2026-11-11

  15. 2010Phase 3 RCT

    Second pivotal trial (Study 2), with a safety extension.

    Falutz J, et al. Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extension. J Acquir Immune Defic Syndr. 2010;53:311-22. PubMed · PMID 20101189 · doi:10.1097/QAI.0b013e3181cbdaff · accessed 2026-11-11

  16. 2010Pooled analysis

    Authors' pooled analysis of both phase 3 trials (806 patients) and their extensions.

    Falutz J, et al. Effects of tesamorelin (TH9507) in HIV-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data. J Clin Endocrinol Metab. 2010;95:4291-304. PubMed · PMID 20554713 · doi:10.1210/jc.2010-0490 · accessed 2026-11-11

  17. 2008Extension

    52-week safety extension of Study 1, with re-randomization to tesamorelin or placebo.

    Falutz J, et al. Long-term safety and effects of tesamorelin, a growth hormone-releasing factor analogue, in HIV patients with abdominal fat accumulation. AIDS. 2008;22:1719-28. PubMed · PMID 18690162 · doi:10.1097/QAD.0b013e32830a5058 · accessed 2026-11-11

  18. 2007Phase 3 RCT

    First pivotal trial (Study 1). Measured visceral fat by CT, lipids and IGF-1 at 26 weeks in adults with HIV.

    Falutz J, et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med. 2007;357:2359-70. PubMed · PMID 18057338 · doi:10.1056/NEJMoa072375 · accessed 2026-11-11

  19. 1999Human PK/PD

    Ipamorelin pharmacokinetics in healthy volunteers. Comparison reference.

    Gobburu JV, et al. Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers. Pharm Res. 1999;16:1412-6. PubMed · PMID 10496658 · doi:10.1023/a:1018955126402 · accessed 2026-11-11

  20. 1998Preclinical

    Original pharmacology of ipamorelin (in vitro, rat and swine). Comparison reference.

    Raun K, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139:552-61. PubMed · PMID 9849822 · doi:10.1530/eje.0.1390552 · accessed 2026-11-11

Abstracts were read for every entry above. Four further secondary analyses were found but not yet read, so they are left out until checked.